Among 60 patients received the combination, 28 were observed objective responses for a confirmed ORR of 47% (95% CI, 34–60), and in patients with high FRα expression (n = 33), the confirmed ORR was 64% (95% CI 45–80), which suggested a significant therapeutic effect of IMGN853 combination with bevacizumab for patients with high FRα recurrent ovarian cancer. This evidence concerns the gene FOLR1 and ovarian cancer.